Nobiten (Nebivolol)

Nebivolol, the active ingredient in Nobiten, is a selective β1‑adrenergic antagonist presented as a tablet for oral use. It is indicated for the management of hypertension and, when appropriate, for heart failure in adult patients, providing blood‑pressure control and improved cardiac function.

GNH USA supplies Nobiten as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets EU quality standards, adheres to Good Manufacturing Practices, and is manufactured under strict regulatory oversight, ensuring consistent potency and safety.

Nebivolol is a selective β1‑blocker used in cardiovascular disease management. Hypertension: reduces systolic and diastolic blood pressure by lowering heart rate and peripheral vascular resistance, helping achieve target BP levels. Heart failure: improves left ventricular ejection fraction and reduces symptoms such as dyspnea and fatigue when added to standard therapy. Post‑myocardial infarction: may lower the risk of recurrent cardiac events and improve long‑term survival in patients with a prior heart attack.

Nebivolol may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: light‑headedness or vertigo, often occurring after the first dose. - Fatigue: feeling unusually tired or weak without exertion. - Headache: mild to moderate head pain, sometimes related to blood‑pressure changes. - Bradycardia: heart rate slower than normal, typically below 60 bpm. - Nausea: upset stomach or urge to vomit, usually transient.

Serious or Rare Side Effects: - Severe bradycardia or heart block: markedly slow heart rate or conduction abnormalities requiring medical attention. - Acute bronchospasm: sudden narrowing of airways in patients with asthma or COPD, potentially life‑threatening. - Allergic reactions: rash, angioedema, or anaphylaxis that may need emergency treatment.

When prescribing Nebivolol, several precautions should be observed to ensure safe use. Dose adjustment in renal impairment: reduce dose according to renal function to avoid accumulation. Monitor heart rate: check for excessive bradycardia, especially in patients with conduction disorders. Caution in asthma or COPD: beta‑blockade may precipitate bronchospasm; use only if benefits outweigh risks. Avoid abrupt discontinuation: taper the dose to prevent rebound hypertension or tachycardia. Pregnancy and lactation: safety not established; prescribe only if potential benefit justifies potential risk. Store at room temperature: keep in the original container, protect from moisture and light.

Nebivolol can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Concomitant use with other beta‑blockers: may cause excessive bradycardia or hypotension. - Calcium channel blockers (verapamil, diltiazem): increase nebivolol plasma levels and risk of AV block. - Strong CYP2D6 inhibitors (paroxetine, quinidine): raise nebivolol concentrations, enhancing adverse effects.

Moderate Interactions (Monitor Closely): - Diuretics: additive hypotensive effect; monitor blood pressure. - Other antihypertensives (ACE inhibitors, ARBs): may produce excessive blood‑pressure lowering. - Insulin or oral hypoglycemics: nebivolol can mask hypoglycemia symptoms; monitor glucose.